RGNX
Biotechnology · Healthcare
Chairman
2009-01-01–present
Chairman
REGENXBIO Inc. (RGNX)Equibles does not estimate personal net worth.
Get an email with a short summary when REGENXBIO Inc. publishes a filing, an earnings call transcript or a press release.
Get RGNX alertsKenneth T. Mills is recorded as Chairman at REGENXBIO Inc. (RGNX) since June 13, 2024. REGENXBIO Inc. reported in an 8-K filed October 16, 2026 that Kenneth T. Mills resigned as board of directors, effective October 21, 2026. The same filing states: “Mr. Mills’ decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.” REGENXBIO Inc. reported in an 8-K filed June 13, 2024 that Kenneth T. Mills was appointed Chairman of the Board. REGENXBIO Inc. reported in an 8-K filed June 13, 2024 that Kenneth T. Mills resigned as President and Chief Executive Officer, effective July 1, 2024. The proxy statement of REGENXBIO Inc. reports total compensation of $5,507,038 for Kenneth T. Mills in fiscal 2024, including a base salary of $340,998. Disclosed compensation is on record for 7 fiscal years. Kenneth T. Mills has spoken on 1 investor event across 1 company, most recently for REGENXBIO Inc. on September 15, 2026. REGENXBIO Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at REGENXBIO Inc. includes Curran M. Simpson (CEO, COO and Board Member), Allan M. Fox (Chairman and Board Member), George Migausky (Chairman and Board Member) and 7 others.
“On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the "Board") of REGENXBIO Inc. (the "Company") effective October 21, 2026.”
“Mr. Mills’ decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.”
“Mr. Mills will continue to serve as a director and has been named Chairman of the Board.”
“We've been in business for roughly 15 years. working on AAV, primarily AAV8 and AAV9 as the base capsids that we've been innovating on. The company is really divided into two different areas.”
2024-06-13–present
2009-01-01–2026-10-21
Start not stated–2024-07-01
RGNX
Biotechnology · Healthcare
Chairman
2009-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | REGENXBIO Inc. (RGNX) | Former President and CEO | $340,998 | $5,507,038 |
| 2023 | REGENXBIO Inc. (RGNX) | Former President and CEO | $676,790 | $5,916,713 |
| 2022 | REGENXBIO Inc. (RGNX) | Former President and CEO | $650,759 | $5,753,713 |
| 2021 | REGENXBIO Inc. (RGNX) | President and CEO | $631,805 | $8,622,941 |
| 2020 | REGENXBIO Inc. (RGNX) | President and CEO | $613,403 | $7,644,087 |
| 2019 | REGENXBIO Inc. (RGNX) | President and CEO | $595,537 | $6,147,269 |
| 2018 | REGENXBIO Inc. (RGNX) | President and CEO | $546,364 | $4,938,199 |
“Mr. Mills’ decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.”
REGENXBIO Inc. (RGNX)